Breast Cancer
Tamoxifen-treated breast cancer may influence progression of atypical endometrial lesions
Published in Women's Health Weekly, July 27th, 2006
Researchers in Italy report, "The purpose of the present study is to prospectively evaluate the effects of tamoxifen on the pathological behavior of endometrial hyperplasias without atypia, diagnosed before the start of adjuvant endocrine therapy, in menopausal patients suffering from breast cancer."
"Twenty-six patients suffering from estrogen-receptor positive breast cancer and candidate to receive adjuvant tamoxifen, were found to be affected by endometrial hyperplasias before the start of endocrine therapy," explained G. Garuti and colleagues from Lodi...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Allergy & Immunology
Avoiding antigens during lactation may not prevent occurrence of allergies in children - Breast Cancer
Racial differences in breast cancer risk may indicate need for updated risk estimates - Renal Cell Carcinoma
Risk of kidney cancer is associated with obesity in women - Uterine Cancer
One third of women treated with tamoxifen develop uterine cancer more than 12 months after therapy - Anesthesia
Laryngeal secretions may not be overly affected by topical anesthesia - Anesthesia
Postoperative pain relief is prolonged with intrathecal midazolam administration - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
